RBC Capital raised the firm’s price target on Stericycle to $69 from $58 and keeps an Outperform rating on the shares after its Q4 earnings beat. The company had previously indicated that its long-term 13%-17% EBITDA CAGR target was achievable starting this year, though the management now provided more visibility into the underlying drivers to inspire confidence in its ability to execute on it, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRCL:
- Stericycle reports Q4 adjusted EPS 54c, consensus 47c
- Stericycle, Inc. Reports Results For The Fourth Quarter 2023
- SRCL Earnings this Week: How Will it Perform?
- Stericycle to Present at Raymond James 45th Annual Institutional Investors Conference in March
- Stericycle price target raised to $50 from $45 at Truist
